These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 9857085)

  • 21. Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.
    Ogino Y; Ohtake N; Nagae Y; Matsuda K; Moriya M; Suga T; Ishikawa M; Kanesaka M; Mitobe Y; Ito J; Kanno T; Ishihara A; Iwaasa H; Ohe T; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5010-4. PubMed ID: 18723347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.
    Baraldi PG; Tabrizi MA; Preti D; Bovero A; Romagnoli R; Fruttarolo F; Zaid NA; Moorman AR; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2004 Mar; 47(6):1434-47. PubMed ID: 14998332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
    Hasegawa M; Nishigaki N; Washio Y; Kano K; Harris PA; Sato H; Mori I; West RI; Shibahara M; Toyoda H; Wang L; Nolte RT; Veal JM; Cheung M
    J Med Chem; 2007 Sep; 50(18):4453-70. PubMed ID: 17676829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptor.
    Baraldi PG; Romagnoli R; Pavani MG; Nuñez Mdel C; Tabrizi MA; Shryock JC; Leung E; Moorman AR; Uluoglu C; Iannotta V; Merighi S; Borea PA
    J Med Chem; 2003 Feb; 46(5):794-809. PubMed ID: 12593659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 2: Benzimidazole-5-sulfonamides.
    Li Y; Kataoka M; Tatsuta M; Yasoshima K; Yura T; Urbahns K; Kiba A; Yamamoto N; Gupta JB; Hashimoto K
    Bioorg Med Chem Lett; 2005 Feb; 15(3):805-7. PubMed ID: 15664861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-Dichloro-benzimidazole derivatives.
    Ng RA; Guan J; Alford VC; Lanter JC; Allan GF; Sbriscia T; Linton O; Lundeen SG; Sui Z
    Bioorg Med Chem Lett; 2007 Feb; 17(3):784-8. PubMed ID: 17095226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligands.
    Lee-Dutra A; Arienti KL; Buzard DJ; Hack MD; Khatuya H; Desai PJ; Nguyen S; Thurmond RL; Karlsson L; Edwards JP; Breitenbucher JG
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6043-8. PubMed ID: 16990005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R).
    Pelletier JC; Chengalvala MV; Cottom JE; Feingold IB; Green DM; Hauze DB; Huselton CA; Jetter JW; Kopf GS; Lundquist JT; Magolda RL; Mann CW; Mehlmann JF; Rogers JF; Shanno LK; Adams WR; Tio CO; Wrobel JE
    J Med Chem; 2009 Apr; 52(7):2148-52. PubMed ID: 19271735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents.
    Hwu JR; Singha R; Hong SC; Chang YH; Das AR; Vliegen I; De Clercq E; Neyts J
    Antiviral Res; 2008 Feb; 77(2):157-62. PubMed ID: 17977606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and structure-activity relationship of imidazo[1,2-a]benzimidazoles as corticotropin-releasing factor 1 receptor antagonists.
    Han X; Pin SS; Burris K; Fung LK; Huang S; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4029-32. PubMed ID: 15982881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.
    Stewart AO; Cowart MD; Moreland RB; Latshaw SP; Matulenko MA; Bhatia PA; Wang X; Daanen JF; Nelson SL; Terranova MA; Namovic MT; Donnelly-Roberts DL; Miller LN; Nakane M; Sullivan JP; Brioni JD
    J Med Chem; 2004 Apr; 47(9):2348-55. PubMed ID: 15084133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, biological activity, QSAR and QSPR study of 2-aminobenzimidazole derivatives as potent H3-antagonists.
    Mor M; Bordi F; Silva C; Rivara S; Zuliani V; Vacondio F; Rivara M; Barocelli E; Bertoni S; Ballabeni V; Magnanini F; Impicciatore M; Plazzi PV
    Bioorg Med Chem; 2004 Feb; 12(4):663-74. PubMed ID: 14759727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 4-(2-Pyridyl)piperazine-1-benzimidazoles as potent TRPV1 antagonists.
    Shao B; Huang J; Sun Q; Valenzano KJ; Schmid L; Nolan S
    Bioorg Med Chem Lett; 2005 Feb; 15(3):719-23. PubMed ID: 15664844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
    Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
    J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl-5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist.
    Mohr P; Decker M; Enzensperger C; Lehmann J
    J Med Chem; 2006 Mar; 49(6):2110-6. PubMed ID: 16539400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Direct observation (NMR) of the efficacy of glucagon receptor antagonists in murine liver expressing the human glucagon receptor.
    Cohen SM; Duffy JL; Miller C; Kirk BA; Candelore MR; Ding VD; Kaczorowski G; Tota LM; Werrmann JG; Wright M; Parmee ER; Tata JR; Zhang BB
    Bioorg Med Chem; 2006 Mar; 14(5):1506-17. PubMed ID: 16256355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides.
    Borza I; Bozó E; Barta-Szalai G; Kiss C; Tárkányi G; Demeter A; Gáti T; Háda V; Kolok S; Gere A; Fodor L; Nagy J; Galgóczy K; Magdó I; Agai B; Fetter J; Bertha F; Keserü GM; Horváth C; Farkas S; Greiner I; Domány G
    J Med Chem; 2007 Mar; 50(5):901-14. PubMed ID: 17290978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor.
    Bosch MP; Campos F; Niubó I; Rosell G; Díaz JL; Brea J; Loza MI; Guerrero A
    J Med Chem; 2004 Jul; 47(16):4041-53. PubMed ID: 15267242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog.
    Rivera N; Everett-Grueter CA; Edgerton DS; Rodewald T; Neal DW; Nishimura E; Larsen MO; Jacobsen LO; Kristensen K; Brand CL; Cherrington AD
    J Pharmacol Exp Ther; 2007 May; 321(2):743-52. PubMed ID: 17308040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.